These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 19395678)

  • 1. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
    Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
    Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
    Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
    Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
    Robb VA; Astrinidis A; Henske EP
    Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.
    Kang YJ; Lu MK; Guan KL
    Cell Death Differ; 2011 Jan; 18(1):133-44. PubMed ID: 20616807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
    Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.
    Li C; Liu X; Liu Y; Zhang E; Medepalli K; Masuda K; Li N; Wikenheiser-Brokamp KA; Osterburg A; Borchers MT; Kopras EJ; Plas DR; Sun J; Franz DN; Capal JK; Mays M; Sun Y; Kwiatkowski DJ; Alayev A; Holz MK; Krueger DA; Siroky BJ; Yu JJ
    Mol Cancer Res; 2017 Oct; 15(10):1318-1330. PubMed ID: 28710231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis.
    Neuman NA; Henske EP
    EMBO Mol Med; 2011 Apr; 3(4):189-200. PubMed ID: 21412983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
    Huang J; Wu S; Wu CL; Manning BD
    Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.
    Himes BE; Obraztsova K; Lian L; Shumyatcher M; Rue R; Atochina-Vasserman EN; Hur SK; Bartolomei MS; Evans JF; Krymskaya VP
    PLoS One; 2018; 13(5):e0197105. PubMed ID: 29758070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.
    Zech R; Kiontke S; Mueller U; Oeckinghaus A; Kümmel D
    J Biol Chem; 2016 Sep; 291(38):20008-20. PubMed ID: 27493206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway.
    Lin Y; Henderson P; Pettersson S; Satsangi J; Hupp T; Stevens C
    FEBS J; 2011 Jan; 278(2):354-70. PubMed ID: 21134130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.
    Priolo C; Ricoult SJ; Khabibullin D; Filippakis H; Yu J; Manning BD; Clish C; Henske EP
    Am J Respir Cell Mol Biol; 2015 Jul; 53(1):33-41. PubMed ID: 25780943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
    Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
    Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
    Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
    PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
    Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
    Makovski V; Haklai R; Kloog Y
    Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.